Timing of kidney treatment in tumor lysis syndrome
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at when to start kidney dialysis for patients in the ICU who develop tumor lysis syndrome (a rapid breakdown of cancer cells after chemotherapy that can harm the kidneys). It aims to find the best timing for this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You were in the intensive care unit (ICU) between 2013 and 2023.
- You have a blood cancer or solid tumor that needed chemotherapy.
- You had tumor lysis syndrome, shown by at least two lab abnormalities like high potassium, high phosphate, high uric acid, or low calcium within a few days of starting chemo.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at two different levels of dosing for continuous dialysis (CRRT) in patients with severe acute kidney injury in the ICU. It aims to find out which dose might be better for recovery.
This study looks at how dialysis (renal replacement therapy) is used for patients in intensive care units (ICUs) with severe acute kidney injury in Latin America. Your participation can help improve care for people with kidney problems.
This study looks at the best timing for starting kidney support treatment (dialysis) in very sick people in the ICU. It may help improve outcomes by comparing different start times.
This trial looks at whether starting dialysis-related care early, aimed at improving blood flow to tissues, can help people in the ICU who have sudden kidney failure. It may help reduce problems related to poor tissue circulation, but it is very specific about ICU illness and current treatments.
This study compares two treatment plans for advanced kidney cancer: having surgery to remove the kidney tumor right away along with immunotherapy drugs (ipilimumab and nivolumab), versus starting the immunotherapy first and doing surgery later. The goal is to see if delaying surgery is just as good or better.
This trial tests a special device that filters parts of the blood to calm inflammation in people with severe acute kidney injury in the ICU. It may help improve recovery and reduce complications by “deactivating” certain immune cells.
Hear when a new Renal Replacement Therapy for Acute Kidney Injury in ICU trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.